| | Oxymetazoline hydrochloride Basic information |
| Product Name: | Oxymetazoline hydrochloride | | Synonyms: | 2-(4-t-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoliniumchloride;2,6-dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazolinehydrochlori;6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-phenohydrochloride;6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenolhydrochloride;OXYMETAZOLINE HCL;OXYMETAZOLINE HYDROCHLORIDE;3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL-6-(1,1-DIMETHYLETHYL)-2,4-DIMETHYLPHENOL, HCL;3-[(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL]-6-(1,1-DIMETHYLETHYL)-2,4-DIMETHYL-PHENOL HYDROCHLORIDE | | CAS: | 2315-02-8 | | MF: | C16H25ClN2O | | MW: | 296.84 | | EINECS: | 219-015-0 | | Product Categories: | PAVABID;Adrenoceptor;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API | | Mol File: | 2315-02-8.mol |  |
| | Oxymetazoline hydrochloride Chemical Properties |
| Melting point | approximate 300℃ (dec.) | | storage temp. | Store at RT | | solubility | H2O: soluble | | form | solid | | color | white | | PH | pH (50g/L, 25℃) : 4.0～6.5 | | Water Solubility | Soluble to 50 mM in water | | Stability: | Toxic | | CAS DataBase Reference | 2315-02-8(CAS DataBase Reference) |
| Hazard Codes | T+ | | Risk Statements | 28 | | Safety Statements | 22-28-36/37/39-45 | | RIDADR | UN 2811 6.1/PG 1 | | WGK Germany | 3 | | RTECS | SK1225000 | | HazardClass | 6.1(a) | | PackingGroup | II | | HS Code | 2933290000 | | Toxicity | LD50 orally in mice: 10 mg/kg (Hotovy) |
| | Oxymetazoline hydrochloride Usage And Synthesis |
| Chemical Properties | Off-White Solid | | Originator | Nasivin,Merck,W. Germany ,1961 | | Uses | muscle relaxant (smooth), cerebral vasodilator | | Uses | Vasoconstrictor, used as a nasal decongestant. An ingredient of Drixin. | | Uses | Oxymetazoline hydrochloride is an α1-AR and α2-AR adrenergic receptor agonist and used as Vasoconstrictor, a nasal decongestant.
| | Definition | ChEBI: A hydrochloride salt resulting from the reaction of equimolar quantities of oxymetazoline and hydrogen chloride. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used to relieve nasal con
estion. | | Manufacturing Process | 10 grams 2,6-dimethyl-3-hydroxy-4-tertiary butylbenzylcyanide (produced by chloromethylation of 2,4-dimethyl-6-tertiary butyl-phenol with formaldehyde and HCl and conversion of the substituted benzyl chloride with NaCN; crystals, from alcohol, melting at 135° to 137°C) and 10.7 grams ethylenediaminemono-p-toluenesulfonate are heated in an oil bath to approximately 235°C for 1? hours, whereby ammonia is evolved. The free base is obtained from the p-toluene-sulfonic acid imidazoline salt which is difficultly soluble in water, by conversion with 50 cc of a 10% NaOH solution. Said base is recrystallized from benzene, and 7.5 grams (62% of the theoretical yield) 2-(2',6'-dimethyl3'-hydroxy-4'-tertiary butylbenzyl)-2-imidazoline, MP 180° to 182°C, are obtained.
By dissolving the free base in an ethyl alcohol solution of hydrochloric acid and adding ether, the hydrochloride can be produced in the usual manner. Said hydrochloride melts, when recrystallized from alcoholic ether, at 300° to 303°C and is decomposed | | Brand name | Ocuclear (Schering-Plough); Visine (Pfizer). | | Therapeutic Function | Nasal decongestant | | Biological Activity | Partial α 2A adrenoceptor agonist and α 1A agonist. Agonist/antagonist activity at 5-HT receptors. |
| | Oxymetazoline hydrochloride Preparation Products And Raw materials |
|
